NASDAQ:GMAB

Genmab A/S Competitors

$35.23
+0.25 (+0.71 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$35.02
Now: $35.23
$35.32
50-Day Range
$30.92
MA: $33.02
$35.12
52-Week Range
$21.80
Now: $35.23
$44.83
Volume340,435 shs
Average Volume627,864 shs
Market Capitalization$23.11 billion
P/E Ratio27.31
Dividend YieldN/A
Beta0.93

Competitors

Genmab A/S (NASDAQ:GMAB) Vs. ZTS, VRTX, TAK, REGN, ALXN, and BGNE

Should you be buying GMAB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Genmab A/S, including Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TAK), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), and BeiGene (BGNE).

Zoetis (NYSE:ZTS) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Institutional & Insider Ownership

92.5% of Zoetis shares are held by institutional investors. Comparatively, 6.2% of Genmab A/S shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Zoetis has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Zoetis and Genmab A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis06902.60
Genmab A/S24802.43

Zoetis currently has a consensus price target of $170.0833, suggesting a potential upside of 1.46%. Genmab A/S has a consensus price target of $42.1429, suggesting a potential upside of 19.62%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Zoetis.

Profitability

This table compares Zoetis and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.50%63.89%14.99%
Genmab A/S50.99%34.40%30.67%

Earnings & Valuation

This table compares Zoetis and Genmab A/S's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.26 billion12.72$1.50 billion$3.6446.05
Genmab A/S$804.57 million28.72$324.68 million$0.5169.08

Zoetis has higher revenue and earnings than Genmab A/S. Zoetis is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Zoetis beats Genmab A/S on 9 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 6.2% of Genmab A/S shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Vertex Pharmaceuticals and Genmab A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042112.88
Genmab A/S24802.43

Vertex Pharmaceuticals currently has a consensus price target of $293.1250, suggesting a potential upside of 33.61%. Genmab A/S has a consensus price target of $42.1429, suggesting a potential upside of 19.62%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Genmab A/S.

Profitability

This table compares Vertex Pharmaceuticals and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Genmab A/S50.99%34.40%30.67%

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Genmab A/S's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.64$1.18 billion$4.2951.14
Genmab A/S$804.57 million28.72$324.68 million$0.5169.08

Vertex Pharmaceuticals has higher revenue and earnings than Genmab A/S. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Genmab A/S on 10 of the 15 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 6.2% of Genmab A/S shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Takeda Pharmaceutical and Genmab A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Takeda Pharmaceutical01002.00
Genmab A/S24802.43

Genmab A/S has a consensus price target of $42.1429, suggesting a potential upside of 19.62%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Profitability

This table compares Takeda Pharmaceutical and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Takeda Pharmaceutical3.04%13.46%5.02%
Genmab A/S50.99%34.40%30.67%

Earnings and Valuation

This table compares Takeda Pharmaceutical and Genmab A/S's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.20 billion1.78$407.02 million$1.789.60
Genmab A/S$804.57 million28.72$324.68 million$0.5169.08

Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Genmab A/S beats Takeda Pharmaceutical on 8 of the 13 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 6.2% of Genmab A/S shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Regeneron Pharmaceuticals and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Genmab A/S50.99%34.40%30.67%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Regeneron Pharmaceuticals and Genmab A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Genmab A/S24802.43

Regeneron Pharmaceuticals currently has a consensus price target of $646.2609, suggesting a potential upside of 28.58%. Genmab A/S has a consensus price target of $42.1429, suggesting a potential upside of 19.62%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Genmab A/S.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Genmab A/S's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.85$2.12 billion$21.4723.41
Genmab A/S$804.57 million28.72$324.68 million$0.5169.08

Regeneron Pharmaceuticals has higher revenue and earnings than Genmab A/S. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Genmab A/S on 9 of the 15 factors compared between the two stocks.

Genmab A/S (NASDAQ:GMAB) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Insider & Institutional Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Genmab A/S and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genmab A/S50.99%34.40%30.67%
Alexion Pharmaceuticals16.32%23.16%14.76%

Analyst Ratings

This is a summary of current ratings and target prices for Genmab A/S and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genmab A/S24802.43
Alexion Pharmaceuticals017512.30

Genmab A/S presently has a consensus target price of $42.1429, suggesting a potential upside of 19.62%. Alexion Pharmaceuticals has a consensus target price of $153.8636, suggesting a potential downside of 6.00%. Given Genmab A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than Alexion Pharmaceuticals.

Earnings & Valuation

This table compares Genmab A/S and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$804.57 million28.72$324.68 million$0.5169.08
Alexion Pharmaceuticals$4.99 billion7.21$2.40 billion$9.7416.80

Alexion Pharmaceuticals has higher revenue and earnings than Genmab A/S. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Genmab A/S has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Genmab A/S on 8 of the 15 factors compared between the two stocks.

Genmab A/S (NASDAQ:GMAB) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Insider & Institutional Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 9.0% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Genmab A/S and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genmab A/S50.99%34.40%30.67%
BeiGene-569.22%-56.81%-39.93%

Analyst Ratings

This is a summary of current ratings and target prices for Genmab A/S and BeiGene, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genmab A/S24802.43
BeiGene21602.44

Genmab A/S presently has a consensus target price of $42.1429, suggesting a potential upside of 19.62%. BeiGene has a consensus target price of $319.3750, suggesting a potential upside of 4.53%. Given Genmab A/S's higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than BeiGene.

Earnings & Valuation

This table compares Genmab A/S and BeiGene's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$804.57 million28.72$324.68 million$0.5169.08
BeiGene$428.21 million65.43$-948,630,000.00($15.80)-19.34

Genmab A/S has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Genmab A/S has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Summary

Genmab A/S beats BeiGene on 10 of the 14 factors compared between the two stocks.


Genmab A/S Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Zoetis logo
ZTS
Zoetis
2.2$167.63+1.3%$79.62 billion$6.26 billion49.74Increase in Short Interest
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$219.39+0.8%$56.78 billion$4.16 billion27.70Analyst Revision
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$17.08+0.7%$53.90 billion$30.20 billion56.94Unusual Options Activity
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$502.60+1.6%$53.84 billion$7.86 billion18.37Analyst Report
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$163.68+3.8%$35.98 billion$4.99 billion38.24Unusual Options Activity
News Coverage
Gap Down
BeiGene logo
BGNE
BeiGene
1.3$305.54+0.7%$28.02 billion$428.21 million-15.12Analyst Downgrade
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.87+0.5%$25.42 billionN/A0.00Dividend Announcement
Insider Selling
Increase in Short Interest
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.27+0.3%$20.90 billion$1.30 billion25.48Insider Selling
CureVac logo
CVAC
CureVac
0.6$109.29+4.8%$20.43 billionN/A0.00Analyst Downgrade
Unusual Options Activity
News Coverage
Gap Down
Catalent logo
CTLT
Catalent
1.7$110.60+0.4%$18.83 billion$3.09 billion70.45Unusual Options Activity
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.88+0.1%$16.29 billion$219.75 million-17.74
Zai Lab logo
ZLAB
Zai Lab
1.4$164.29+0.4%$14.55 billion$12.98 million-54.22Analyst Report
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$79.40+0.8%$14.44 billion$1.70 billion18.17News Coverage
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$29.98+0.7%$14.17 billion$3.07 billion-52.60Analyst Report
Grifols logo
GRFS
Grifols
1.3$17.98+1.6%$12.36 billion$5.71 billion16.05Upcoming Earnings
News Coverage
Gap Up
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.75+0.7%$11.74 billion$16.89 billion-2.92Decrease in Short Interest
News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$65.01+1.4%$10.81 billion$2.32 billion53.73
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$30.03+0.9%$10.68 billion$8.60 billion-5.51
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$168.90+0.3%$9.51 billion$2.16 billion53.28Analyst Report
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.68+0.1%$9.45 billionN/A0.00Increase in Short Interest
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.73+1.0%$9.07 billion$1.45 billion19.27Analyst Report
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$55.12+0.3%$8.21 billion$40.56 million-16.16
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$158.19+3.7%$8.01 billion$3.34 million-20.54Unusual Options Activity
News Coverage
Gap Down
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$108.72+0.8%$7.28 billion$103.71 million-24.77Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.65+0.5%$7.02 billion$87.99 million-80.54News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.90+0.0%$6.86 billion$311.33 million-127.27Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$121.95+1.8%$6.55 billion$14.98 million-14.85Analyst Downgrade
News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.78+2.3%$6.30 billion$150,000.00-21.12High Trading Volume
Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78+0.6%$5.74 billion$1.12 billion84.96Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80+1.2%$5.70 billion$380.83 million-9.18Analyst Report
News Coverage
Perrigo logo
PRGO
Perrigo
2.3$41.62+1.1%$5.56 billion$4.84 billion-693.55
Allakos logo
ALLK
Allakos
1.7$104.50+3.5%$5.55 billionN/A-38.14Insider Selling
Gap Down
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20+0.8%$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.3$77.90+0.6%$5.45 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.15+0.3%$5.19 billion$1.00 billion-11.99Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.40+1.9%$4.62 billionN/A-6.06Analyst Revision
Gap Down
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.64+1.2%$4.36 billion$6.87 million-7.21Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25+0.4%$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64+4.1%$4.16 billion$1.11 billion24.96Analyst Report
Gap Up
I-Mab logo
IMAB
I-Mab
1.2$57.00+0.2%$4.10 billion$4.31 million-1.97Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90+3.2%$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69+0.6%$3.82 billion$117.91 million-11.09News Coverage
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94+2.4%$3.72 billionN/A0.00Analyst Report
Increase in Short Interest
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57+1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03+5.8%$3.58 billionN/A-20.81Analyst Report
Gap Down
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00+1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
LEGN
Legend Biotech
1.2$26.00+0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.59+0.8%$3.42 billion$306.98 million-6.95News Coverage
Insmed logo
INSM
Insmed
1.2$33.07+1.7%$3.42 billion$136.47 million-12.72News Coverage
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.15+0.2%$3.38 billion$339.08 million-12.30Analyst Report
High Trading Volume
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.